Open AccessTime Course of Evolution of Disability and Cause‐Specific Mortality After Ischemic Stroke: Implications for Trial Design
Author(s) -
Ganesh Aravind,
LuengoFernandez Ramon,
Wharton Rose M.,
Gutnikov Sergei A.,
Silver Louise E.,
Mehta Ziyah,
Rothwell Peter M.
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.005788
Subject(s) - medicine , hazard ratio , stroke (engine) , modified rankin scale , population , cause of death , cohort , national death index , confidence interval , pediatrics , ischemic stroke , disease , ischemia , mechanical engineering , environmental health , engineering
Background Outcome in stroke trials is often based on a 3‐month modified Rankin scale ( mRS ). How 3‐month mRS relates to longer‐term outcomes will depend on late recovery, delayed stroke‐related deaths, recurrent strokes, and nonstroke deaths. We evaluated 3‐month mRS and death/disability at 1 and 5 years in a population‐based cohort study. Methods and Results In 3‐month survivors of ischemic stroke (Oxford Vascular Study; 2002‐2014), we related 3‐month mRS to disability (defined as mRS >2) at 1 and 5 years and/or death rates (age/sex adjusted). Accrual of disability and index‐stroke‐related and nonstroke deaths in each poststroke year was categorized according to 3‐month mRS . Among 1606 patients with acute ischemic stroke, 181 died within 3 months, but 126 index‐stroke‐related deaths and 320 other deaths occurred during the subsequent 4866 patient‐years of follow‐up up to 5 years. Although 69/126 (54.8%) post‐3‐month index‐stroke‐related deaths occurred after 1 year, mRS >2 at 1 year strongly predicted these deaths (adjusted hazard ratio=21.94, 95% CI 7.88‐61.09, P <0.0001). Consequently, a 3‐month mRS >2 was a strong independent predictor of death at both 1 year (adjusted hazard ratio=6.67, 95%CI 4.16‐10.69, P <0.0001) and 5 years (adjusted hazard ratio=2.93, 95%CI 2.38‐3.60, P <0.0001). Although mRS improved by ≥1 point from 3 months to 1 year in 317/1266 (25.0%) patients with 3‐month mRS ≥1, improvement in mRS after 1 year was limited (improvement by ≥1 point: 91/858 [10.6%]; improvement to mRS ≤2: 13/353 [3.7%]). Conclusions Our results reaffirm use of the 3‐month mRS outcome in stroke trials. Although later recovery does occur, extending follow‐up to 1 year would capture most long‐term stroke‐related disability. However, administrative mortality follow‐up beyond 1 year has the potential to demonstrate translation of early disability gains into additional reductions in long‐term mortality without much erosion by non‐stroke‐related deaths.